Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.810
+0.020 (1.12%)
At close: Mar 28, 2025, 4:00 PM
1.821
+0.011 (0.60%)
After-hours: Mar 28, 2025, 7:53 PM EDT
Zentalis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Zentalis Pharmaceuticals stock have an average target of 8.53, with a low estimate of 2.20 and a high estimate of 20. The average target predicts an increase of 371.27% from the current stock price of 1.81.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Zentalis Pharmaceuticals stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Hold Reiterates $4 | Hold | Reiterates | $4 | +120.99% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +452.49% | Mar 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +452.49% | Mar 17, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $8 → $6 | Hold | Maintains | $8 → $6 | +231.49% | Jan 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $10 | Strong Buy | Maintains | $20 → $10 | +452.49% | Jan 29, 2025 |
Financial Forecast
Revenue This Year
n/a
from 67.43M
Revenue Next Year
20.87M
EPS This Year
-2.61
from -2.33
EPS Next Year
-2.52
from -2.61
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 177.6M | 116.6M | ||
| Avg | n/a | 20.9M | 49.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 458.5% | ||
| Avg | - | - | 136.4% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.73 | -1.71 | -1.39 | ||
| Avg | -2.61 | -2.52 | -2.42 | ||
| Low | -3.25 | -3.53 | -3.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.